Get started
Author

Shepherd Mudzingwa

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
2022 · Nicholas I Paton, Joseph Musaazi, et al. · The Lancet HIV · 138
PDF
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
2017 · Nicholas I Paton, Cissy Kityo, et al. · The Lancet HIV · 79
PDF
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
2017 · James G Hakim, Jennifer Thompson, et al. · The Lancet Infectious Diseases · 43
PDF
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
2022 · Pauline Amuge, Abbas Lugemwa, et al. · The Lancet HIV · 36
PDF
Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial
2018 · Abraham Siika, Leanne McCabe, et al. · Clinical Infectious Diseases · 33
PDF
Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
2018 · Jane Mallewa, Alexander J Szubert, et al. · The Lancet HIV · 31
PDF
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
2022 · Anna Turkova, Hylke Waalewijn, et al. · The Lancet HIV · 24
PDF
Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study
2024 · Tshepiso Mbangiwa, Aude Sturny-Leclère, et al. · The Lancet Microbe · 17
PDF
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
2023 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 14
PDF
Malnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial
2024 · Kanta Chandwe, Mutsa Bwakura-Dangarembizi, et al. · Nature Communications · 13
PDF
Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial
2023 · Tom G Jacobs, Vivian Mumbiro, et al. · Clinical Infectious Diseases · 12
PDF
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial
2018 · Jennifer A Thompson, Cissy Kityo, et al. · Clinical Infectious Diseases · 11
PDF
Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial
2026 · Julia A Bielicki, Michelle Clements, et al. · The Lancet · 5
A Trial of Trimethoprim–Sulfamethoxazole in Pregnancy to Improve Birth Outcomes
2025 · Bernard Chasekwa, Fortunate Munhanzi, et al. · New England Journal of Medicine · 5
PDF
The Effect of Chloroquine on Circulating Platelet Survival in the Rat
1999 · Eme Osim, Shepherd Mudzingwa, et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 4
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial
2026 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 3
An adaptive multiarm randomised trial of biomedical and psychosocial interventions to improve convalescence following severe acute malnutrition in sub-Saharan Africa: Co-SAM trial protocol
2025 · Mutsa Bwakura-Dangarembizi, Beatrice Amadi, et al. · BMJ Open · 3
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2
Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial
2024 · Hylke Waalewijn, Roeland E Wasmann, et al. · Journal of the Pediatric Infectious Diseases Society · 2
PDF
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia
2023 · Chishala Chabala, Tom G Jacobs, et al. · Journal of the Pediatric Infectious Diseases Society · 2
PDF
Tablets are more acceptable and give fewer problems than syrups among young HIV-infected children in resource limited settings in the ARROW trial.
2010 · Patricia Nahirya-Ntege, Mutsa Bwakura‐Dangarembizi, et al. · 2
Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trial
2026 · Tom G. Jacobs, Vivian Mumbiro, et al. · EClinicalMedicine · 1
Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
2026 · Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, et al. · The Lancet
Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial
2026 · Anne E M Kamphuis, Nicolas Salvadori, et al. · The Lancet HIV
Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment
2026 · Laize Sílvia dos Anjos Botas Beca, Vivian Mumbiro, et al. · Journal of Antimicrobial Chemotherapy
Works count: 32
Citation count: 544
H-index: 12
I10-index: 14
Year
Topic
Type